Jennison Associates
NXTC icon

Jennison Associates’s NextCure NXTC Stock Holding History

Jennison Associates’s Portfolio NXTC Stock Details NXTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-38,864
Closed -$10M – 672
2020
Q2 		$10M Buy
38,864
+161
+0.4% +$61.3K 0.01% 373
2020
Q1 		$17.2M Buy
38,703
+30,370
+364% +$16.2M 0.02% 278
2019
Q4 		$5.63M Buy
+8,333
New +$4.18M 0.01% 423

Other funds holding NXTC

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
CPX
Canaan Partners X Menlo Park, California $74.7M AUM 151.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $96.1B AUM 40.06% 1-Year Est. Return

Jennison Associates's NXTC Position: Q3 2020 in Review

Jennison Associates sold out of NextCure (NXTC) in Q3 2020, closing a stake of 38,864 shares — an estimated $10M sold.

Jennison Associates first reported a position in NXTC in Q4 2019 and held it in 3 quarters. The position peaked at $17.2M in Q1 2020. 75 funds tracked by Wall St. Rank hold NXTC as of Q3 2020.

  • Jennison Associates reported no remaining NextCure position as of Q3 2020 after selling out during the quarter.
  • Jennison Associates sold 38,864 NextCure shares in Q3 2020, an estimated $10M.
  • Jennison Associates first reported a position in NextCure in Q4 2019 and held it in 3 quarters.
  • Jennison Associates's NextCure position peaked at $17.2M in Q1 2020.
  • 75 funds tracked by Wall St. Rank held NextCure as of Q3 2020.

Based on Jennison Associates's 13F filing for Q3 2020, filed 4 Nov 2020.